论文部分内容阅读
目的:探讨淫羊藿对哮喘大鼠模型气道高反应性的影响。方法:将SD大鼠60只随机分为正常对照组、哮喘模型组、地塞米松组、及淫羊藿低、中、高剂量组,每组10只。实验开始第0天,大鼠ip含卵蛋白100μg和氢氧化铝100 mg的生理盐水溶液,第14天起予1%卵蛋白激发3周,第35天起2%卵蛋白激发1周。治疗组第14天起给予低、中、高剂量淫羊藿0.25,0.5,1 g·kg-1,或地塞米松1 mg·kg-1,每天1次,连续4周。正常组与模型组用等量生理盐水代替。采用Buxco肺功能仪有创法检测气道反应性;ELISA法检测肺泡灌洗液细胞因子干扰素(INF)-γ,白介素(IL)-4,IL-5,IL-13,IL-10,IL-6,肿瘤坏死因子(TNF)-α及转化生长因子-β(TGF-β);肺组织HE,PAS及Masson三色染色评价观察小鼠肺组织炎症、气道黏液分泌水平及气道壁周围胶原沉积水平。结果:与正常组相比,模型组气道阻力(RL)明显升高,肺顺应性(Cdyn)明显降低(P<0.01);肺泡灌洗液IL-4,IL-5,IL-13,TGF-β1和TNF-α水平显著升高(P<0.05,P<0.01),而INF-γ水平显著下降(P<0.05);气道炎症指数、气道黏液评分、及气道周围胶原评分显著升高(P<0.01)。与模型组相比,淫羊藿低、中、高剂量组可不同程度降低气道阻力,改善肺顺应性(P<0.05,P<0.01);淫羊藿高剂量组可显著降低哮喘模型组肺泡灌洗液中IL-4(P<0.05),IL-5和IL-13水平(P<0.01);中剂量组可显著降IL-5和IL-13水平(P<0.05,P<0.01),且能显著升高IL-10水平(P<0.05);低剂量组可显著降低IL-5水平(P<0.05);淫羊藿中、高剂量治疗组气道炎症指数、气道黏液评分,以及气道周围胶原面积显著降低(P<0.05,P<0.05)。结论:淫羊藿可改善哮喘模型气道高反应性,这与其抑制气道炎症,及改善气道重塑相关。
Objective: To investigate the effects of Epimedium on airway hyperresponsiveness in asthmatic rat models. Methods: 60 SD rats were randomly divided into normal control group, asthma model group, dexamethasone group, and Epimedium low, middle and high dose groups, 10 in each group. On the 0th day after the start of the experiment, the rats had ip containing 100 μg of egg albumin and 100 mg of aluminum hydroxide in saline solution. On the 14th day, 1% egg protein was used for 3 weeks, and on the 35th day, 2% egg protein was used for 1 week. On the 14th day of treatment group, low-, medium- and high-dose Epimedium were given 0.25, 0.5, 1 g·kg-1, or dexamethasone 1 mg·kg-1 once a day for 4 weeks. The normal group and the model group were replaced with the same amount of physiological saline. Airway responsiveness was measured by the invasive method using Buxco spirometer; IFN-γ, IL-4, IL-5, IL-13 and IL-10 were detected by ELISA. IL-6, tumor necrosis factor (TNF)-α, and transforming growth factor-β (TGF-β); lung, HE, PAS and Masson trichrome staining evaluation of lung inflammation, airway mucus secretion and airway Collagen deposition levels around the wall. Results: Compared with the normal group, the airway resistance (RL) in the model group was significantly increased, and the lung compliance (Cdyn) was significantly decreased (P<0.01); bronchoalveolar lavage fluid IL-4, IL-5, IL-13, TGF-β1 and TNF-α levels were significantly increased (P<0.05, P<0.01), while INF-γ levels were significantly decreased (P<0.05); airway inflammation index, airway mucus score, and airway collagen scores Significantly increased (P<0.01). Compared with the model group, epimedium low, middle and high dose groups can reduce airway resistance and improve lung compliance in different degrees (P<0.05, P<0.01); Epimedium high dose group can significantly reduce the asthma model group IL-4 (P<0.05), IL-5 and IL-13 levels in bronchoalveolar lavage fluid (P<0.01); IL-5 and IL-13 levels were significantly reduced in the middle dose group (P<0.05, P<0.01). , And can significantly increase IL-10 levels (P <0.05); low dose group can significantly reduce IL-5 levels (P <0.05); epimedium medium and high dose treatment group airway inflammation index, airway mucus The scores and area of collagen around the airway were significantly decreased (P<0.05, P<0.05). CONCLUSION: Epimedium can improve airway hyperresponsiveness in asthmatic models, which is associated with its inhibition of airway inflammation and improvement of airway remodeling.